Find Temsirolimus manufacturers, exporters & distributors on PharmaCompass

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

8 API Suppliers, 5 USDMF, 2 EU WC, 2 NDC API, 4 Listed Suppliers, $ API Reference Price

8 API Suppliers
5 USDMF
2 EU WC
2 NDC API
4 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

9 FDF Dossiers, 3 FDA Orange Book, 3 Europe, 1 Canada, 1 South Africa, 1 Listed Dossiers

9 FDF Dossiers
3 FDA Orange Book
3 Europe
1 Canada
1 South Africa
1 Listed Dossiers

DIGITAL CONTENT

8 NEWS #PharmaBuzz

media
8 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 2 Finished Drug Prices

globalSalesInformation
1 US Medicaid Prescriptions
2 Finished Drug Prices

MARKET PLACE

2 APIs, 1 FDF Dossiers

marketPlace
2 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

8 US Patents, 3 Health Canada Patents

patents
8 US Patents
3 Health Canada Patents

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

158,619

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Cci-779, Torisel, 162635-04-3, 624kn6gm2t, Chembl1201182, Cci 779

Molecular Formula

C₅₆H₈₇NO₁₆

Molecular Weight

1030.3 g/mol

InChI Key

CBPNZQVSJQDFBE-FUXHJELOSA-N

FDA UNII

624KN6GM2T

Temsirolimus is a Kinase Inhibitor. The mechanism of action of temsirolimus is as a Protein Kinase Inhibitor.

1 2D Structure

Temsirolimus

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate

2.1.2 InChI

InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1

2.1.3 InChI Key

CBPNZQVSJQDFBE-FUXHJELOSA-N

2.1.4 Canonical SMILES

CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC

2.1.5 Isomeric SMILES

C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC

2.2 Other Identifiers

2.2.1 UNII

624KN6GM2T

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Cci 779

2. Cci-779

3. Rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate)

4. Torisel

2.3.2 Depositor-Supplied Synonyms

1. Cci-779

2. Torisel

3. 162635-04-3

4. 624kn6gm2t

5. Chembl1201182

6. Cci 779

7. Ncgc00167518-01

8. Rapamycin 42-(2,2-bis(hydroxymethyl)propionate)

9. Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]

10. Rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate)

11. (1r,2r,4s)-4-{(2r)-2-[(3s,6r,7e,9r,10r,12r,14s,15e,17e,19e,21s,23s,26r,27r,30s,34as)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3h-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate

12. Chebi:79699

13. Temserolimus

14. Nsc-683864

15. Mfcd00934421

16. Temsirolimus (cci-779, Nsc 683864)

17. Temsirolimus [usan]

18. Temsirolimus - Torisel

19. Temsirolimus [mi]

20. Temsirolimus [inn]

21. Temsirolimus [jan]

22. Dsstox_cid_20945

23. Dsstox_rid_79605

24. Temsirolimus [vandf]

25. Unii-624kn6gm2t

26. Dsstox_gsid_40945

27. Schembl18792

28. Temsirolimus [mart.]

29. 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin

30. Temsirolimus [who-dd]

31. Way-cci 779

32. Gtpl5892

33. Temsirolimus [ema Epar]

34. Dtxsid2040945

35. Hsdb 7931

36. Temsirolimus, >=98% (hplc)

37. Temsirolimus [orange Book]

38. 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin

39. Temsirolimus [usan:inn:ban:jan]

40. Tox21_112515

41. Bdbm50343413

42. S1044

43. Akos025142069

44. Am84554

45. Ccg-264790

46. Cs-0129

47. Ncgc00167518-02

48. Ncgc00167518-05

49. Ncgc00167518-09

50. Hy-50910

51. Cas-162635-04-3

52. T3574

53. Ab01274736-01

54. Ab01274736_02

55. 635t043

56. Sr-01000898799

57. J-009958

58. Q7699074

59. Sr-01000898799-3

60. Brd-k08177763-001-02-6

61. A4i

2.4 Create Date

2006-07-28

3 Chemical and Physical Properties

Molecular Formula	C₅₆H₈₇NO₁₆
Molecular Weight	1030.3 g/mol
XLogP3	5.6
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	16
Rotatable Bond Count	11
Exact Mass	1029.60248569 g/mol
Monoisotopic Mass	1029.60248569 g/mol
Topological Polar Surface Area	242 Å²
Heavy Atom Count	73
Formal Charge	0
Complexity	2010
Isotope Atom Count	0
Defined Atom Stereocenter Count	15
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	4
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Torisel
PubMed Health	Temsirolimus (Injection)
Drug Classes	Antineoplastic Agent
Active Ingredient	Temsirolimus
Dosage Form	Solution
Route	Intravenous
Strength	25mg/ml (25mg/ml)
Market Status	Prescription
Company	Pf Prism Cv

2 of 2
Drug Name	Torisel
PubMed Health	Temsirolimus (Injection)
Drug Classes	Antineoplastic Agent
Active Ingredient	Temsirolimus
Dosage Form	Solution
Route	Intravenous
Strength	25mg/ml (25mg/ml)
Market Status	Prescription
Company	Pf Prism Cv

4.2 Therapeutic Uses

Temsirolimus is indicated for the treatment of advanced renal cell carcinoma. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for TORISEL (temsirolimus) kit (June 2011). Available from, as of July 5, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95b7dc92-2180-42f1-8699-3c28f609e674

4.3 Drug Warning

Anaphylaxis, dyspnea, flushing, and chest pain have been reported. Temsirolimus should be used with caution in patients with known hypersensitivity to the drug or its metabolites (eg, sirolimus), polysorbate 80, or any other ingredient in the formulation.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 1242

Pretreatment with an antihistamine prior to each dose of temsirolimus is recommended to prevent hypersensitivity reactions. Temsirolimus should be used with caution in patients with known hypersensitivity to antihistamines or with conditions requiring avoidance of antihistamines.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 1242

The safety and pharmacokinetics of temsirolimus were evaluated in a dose escalation phase 1 study in 110 patients with normal or varying degrees of hepatic impairment. Patients with baseline bilirubin >1.5 x ULN experienced greater toxicity than patients with baseline bilirubin /= grade 3 adverse reactions and deaths, including deaths due to progressive disease, were greater in patients with baseline bilirubin >1.5 x ULN. temsirolimus is contraindicated in patients with bilirubin >1.5 x ULN due to increased risk of death. Use caution when treating patients with mild hepatic impairment. Concentrations of temsirolimus and its metabolite sirolimus were increased in patients with elevated AST or bilirubin levels. If temsirolimus must be given in patients with mild hepatic impairment (bilirubin >1 - 1.5 x ULN or AST >ULN but bilirubin

No clinical studies were conducted with temsirolimus in patients with decreased renal function. Less than 5% of total radioactivity was excreted in the urine following a 25 mg intravenous dose of (14)C-labeled temsirolimus in healthy subjects. Renal impairment is not expected to markedly influence drug exposure, and no dosage adjustment of temsirolimus is recommended in patients with renal impairment.

For more Drug Warnings (Complete) data for Temsirolimus (29 total), please visit the HSDB record page.

4.4 Drug Indication

* Renal-cell carcinoma:

Torisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors.

* Mantle-cell lymphoma:

Torisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

MTOR Inhibitors

Agents that inhibit the activity of TOR SERINE-THREONINE KINASES. (See all compounds classified as MTOR Inhibitors.)

5.2 FDA Pharmacological Classification

5.2.1 Active Moiety

TEMSIROLIMUS

5.2.2 FDA UNII

624KN6GM2T

5.2.3 Pharmacological Classes

Mechanisms of Action [MoA] - Protein Kinase Inhibitors

5.3 ATC Code

L01XE09

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EG - Mammalian target of rapamycin (mtor) kinase inhibitors

L01EG01 - Temsirolimus

5.4 Absorption, Distribution and Excretion

Following administration of a single 25 mg dose of temsirolimus in patients with cancer, mean temsirolimus Cmax in whole blood was 585 ng/mL (coefficient of variation, CV =14%), and mean AUC in blood was 1627 ng.hr/mL (CV=26%). Typically Cmax occurred at the end of infusion. Over the dose range of 1 mg to 25 mg, temsirolimus exposure increased in a less than dose proportional manner while sirolimus exposure increased proportionally with dose. Following a single 25 mg intravenous dose in patients with cancer, sirolimus AUC was 2.7-fold that of temsirolimus AUC, due principally to the longer half-life of sirolimus.

Following a single 25 mg intravenous dose, mean steady-state volume of distribution of temsirolimus in whole blood of patients with cancer was 172 liters. Both temsirolimus and sirolimus are extensively partitioned into formed blood elements.

Following a single 25 mg dose of temsirolimus in patients with cancer, temsirolimus mean (CV) systemic clearance was 16.2 (22%) L/hr.

It is not known whether temsirolimus is excreted into human milk...

Following IV administration of a single radiolabeled dose of temsirolimus, approximately 78% of the total radioactivity is recovered in feces and 4.6% in urine within 14 days.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 1243

5.5 Metabolism/Metabolites

Sirolimus, an active metabolite of temsirolimus, is the principal metabolite in humans following intravenous treatment. The remainder of the metabolites account for less than 10% of radioactivity in the plasma.

Temsirolimus is metabolized by hydrolysis to sirolimus, the principal active metabolite. Both temsirolimus and sirolimus also are metabolized by cytochrome P-450 (CYP) isoenzyme 3A4. Although temsirolimus is metabolized to sirolimus, temsirolimus itself exhibits antitumor activity and is not considered a prodrug.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 1243

The in vitro metabolism of temsirolimus, (rapamycin-42-[2,2-bis-(hydroxymethyl)]-propionate), an antineoplastic agent, was studied using human liver microsomes as well as recombinant human cytochrome P450s, namely CYP3A4, 1A2, 2A6, 2C8, 2C9, 2C19, and 2E1. Fifteen metabolites were detected by liquid chromatography (LC)-tandem mass spectrometry (MS/MS or MS/MS/MS). CYP3A4 was identified as the main enzyme responsible for the metabolism of the compound. Incubation of temsirolimus with recombinant CYP3A4 produced most of the metabolites detected from incubation with human liver microsomes, which was used for large-scale preparation of the metabolites. By silica gel chromatography followed by semipreparative reverse-phase high-performance liquid chromatography, individual metabolites were separated and purified for structural elucidation and bioactivity studies. The minor metabolites (peaks 1-7) were identified as hydroxylated or desmethylated macrolide ring-opened temsirolimus derivatives by both positive and negative mass spectrometry (MS) and MS/MS spectroscopic methods. Because these compounds were unstable and only present in trace amounts, no further investigations were conducted. Six major metabolites were identified as 36-hydroxyl temsirolimus (M8), 35-hydroxyl temsirolimus (M9), 11-hydroxyl temsirolimus with an opened hemiketal ring (M10 and M11), N- oxide temsirolimus (M12), and 32-O-desmethyl temsirolimus (M13) using combined LC-MS, MS/MS, MS/MS/MS, and NMR techniques. Compared with the parent compound, these metabolites showed dramatically decreased activity against LNCaP cellular proliferation.

PMID:17540708 Cai P et al; Drug Metab Dispos 35 (9): 1554-63 (2007)

5.6 Biological Half-Life

Temsirolimus exhibits a bi-exponential decline in whole blood concentrations and the mean half-lives of temsirolimus and sirolimus were 17.3 hr and 54.6 hr, respectively.

5.7 Mechanism of Action

Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor.

Temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR) kinase, is an antineoplastic agent. Receptor tyrosine kinases (RTKs) are involved in the initiation of various cascades of intracellular signaling events that lead to cell proliferation and/or influence processes critical to cell survival and tumor progression (eg, angiogenesis, metastasis), inhibition of apoptosis. Although the exact mechanism of action has not been fully elucidated, temsirolimus binds with high affinity to the intracellular protein FK506 binding protein-12 in vitro, forming a drug-protein complex that inhibits the activation of mTOR, which regulates cell division. This disruption of mTOR signaling suppresses proteins that regulate cell-cycle progression, thereby blocking cells in the G1 phase of the cell cycle. Inhibition of mTOR by temsirolimus also has been associated with reduced expression of hypoxia inducible factor 1alpha and 2alpha (HIF-1alpha and HIF-2alpha) in vitro, resulting in reduced expression of vascular endothelial growth factor (VEGF) and a potential antiangiogenic effect.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 1243

Temsirolimus inhibited T lymphocyte activity in mice, but the effects were reversible and T lymphocyte activity returned to normal within 24 hours of discontinuance. No consistent effect on lymphocyte population or activation was demonstrated in humans. However, infections may result from immunosuppression.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 1243

The phosphatidylinositol 3-kinase (PI3-K)/mammalian target of rapamycin (mTOR) signal transduction pathway integrates signals from multiple receptor tyrosine kinases to control cell proliferation and survival. Key components of the pathway are the lipid kinase PI3-K, the small guanosine triphosphate-binding protein Rheb, and the protein kinases Akt and mTOR. Important natural inhibitors of the pathway include the lipid phosphatase PTEN and the tuberous sclerosis complex. Several components of this pathway are targeted by investigational antineoplastic agents. Rapamycin (sirolimus), the prototypic mTOR inhibitor, exhibits activity in acute myeloid leukemia. Three rapamycin analogs, temsirolimus, everolimus, and AP23573, are in clinical trials for various hematologic malignancies. Temsirolimus has produced a 38% overall response rate in relapsed mantle cell lymphoma, and AP23573 has demonstrated activity in acute leukemia. Everolimus is undergoing clinical testing in lymphoma (Hodgkin and non-Hodgkin) and multiple myeloma. In addition, perifosine, an inhibitor of Akt activation that exhibits substantial antimyeloma activity in preclinical models, is being examined in relapsed multiple myeloma. Based on results obtained to date, it appears that inhibitors of the PI3-K/mTOR pathway hold promise as single agents and in combination for hematologic malignancies.

PMID:16916489 Witzig TE, Kaufmann SH; Curr Treat Options Oncol 7 (4): 285-94 (2006)

For more Mechanism of Action (Complete) data for Temsirolimus (7 total), please visit the HSDB record page.

API SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Export","activeIngredients":"TEMSIROLIMUS","year":"2021","qtr":"Q1","strtotime":1615228200,"product":"TEMSIROLIMUS BATCH NO. 19221006 MFG. DT. FEB 2021 RETEST DT. JAN 2024","address":"302, SAKAR - III, NR. OLD HIGHCOURTOFF. INCOME TAX OFFICE,","city":"AHMEDABAD ,GUJARAT","supplier":"CONCORD BIOTECH","supplierCountry":"INDIA","foreign_port":"MILAN","customer":"THERMOFISHER SCIENTIFIC","customerCountry":"ITALY","quantity":"0.02","actualQuantity":"0.02","unit":"KGS","unitRateFc":"1313513.9","totalValueFC":"25999.1","currency":"USD","unitRateINR":94638673.5,"date":"09-Mar-2021","totalValueINR":"1892773.47","totalValueInUsd":"25999.1","indian_port":"AHMEDABAD AIR","hs_no":"29420090","bill_no":"9231200","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"302, SAKAR - III, NR. OLD HIGHCOURTOFF. INCOME TAX OFFICE,, AHMEDABAD ,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1664130600,"product":"TEMSIROLIMUS - BATCH NO: 1919222004, MFG","address":"1482 1486 TRASAD ROAD,DHOLKA","city":"AHMEDABAD,GUJARAT","supplier":"CONCORD BIOTECH","supplierCountry":"INDIA","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"TO ORDER,","customerCountry":"UNITED STATES","quantity":"0.00","actualQuantity":"0.004","unit":"KGS","unitRateFc":"1000000","totalValueFC":"3631.1","currency":"USD","unitRateINR":72750000,"date":"26-Sep-2022","totalValueINR":"291000","totalValueInUsd":"3631.1","indian_port":"AHMEDABAD AIR","hs_no":"29420090","bill_no":"4442559","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"1482 1486 TRASAD ROAD,DHOLKA, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1719772200,"product":"TEMSIROLIMUS BATCH NO.1919A223002,MFG. DT. SEP 2023,RETEST DT.AUG 2026","address":"1482-1486, TRASAD ROAD,","city":"AHMEDABAD ,GUJARAT","supplier":"CONCORD BIOTECH","supplierCountry":"INDIA","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"TO ORDER","customerCountry":"UNITED STATES","quantity":"0.03","actualQuantity":"0.03","unit":"KGS","unitRateFc":"950000","totalValueFC":"27658.1","currency":"USD","unitRateINR":77065800,"date":"01-Jul-2024","totalValueINR":"2311974","totalValueInUsd":"27658.1","indian_port":"Ahmedabad Air","hs_no":"29420090","bill_no":"2102191","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"1482-1486, TRASAD ROAD,, AHMEDABAD ,GUJARAT","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1712255400,"product":"TEMSIROLIMUS IH (RE IMPORT RETURN OF MATERIAL DUE TO SPECIFICATIONISSUE VIDE SB NO:7727410 DATE:25.01.2022) AS INV","address":"211, VINDHYA APARTMENTS,","city":"HYDERABAD. AP.","supplier":"JSC PHARMASYNTEZ","supplierCountry":"RUSSIA","foreign_port":"SHEREMETYEVO","customer":"ROERICH HEALTH CARE ","customerCountry":"INDIA","quantity":"0.09","actualQuantity":"90","unit":"GMS","unitRateFc":"1500","totalValueFC":"136362.3","currency":"USD","unitRateINR":"126525","date":"05-Apr-2024","totalValueINR":"11387250","totalValueInUsd":"136362.3","indian_port":"Hyderabad Air","hs_no":"29420090","bill_no":"2889773","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHEREMETYEVO","supplierAddress":"OFFICE 3 BLDG 23 KRASNOGVARDEISKAYAST IRKUTSK RUSSIAN FEDERATION664007RUSSIA RU","customerAddress":"211, VINDHYA APARTMENTS,"}]